Austria Strips Pfizer Of Lipitor Patent
The U.S. drug maker’s patent was successfully challenged by India’s largest pharmaceutical company, which is also challenging the Lipitor patent in other countries, including the U.S.
Pfizer said Tuesday it would appeal the decision, which only applies to the Austrian market.
Pfizer said it was confident it would, on appeal, be able to make a compelling argument in support of its patent.
To view the full article, register now.